Altered monocyte and fibrocyte phenotype and function in scleroderma interstitial lung disease: Reversal by caveolin-1 scaffolding domain peptide

Fibrogenesis and Tissue Repair

Volumn 4, Issue 1, 2011, Pages

  Tourkina, Elena ^a   Bonner, Michael ^a   Oates, James ^a   Hofbauer, Ann ^a   Richard, Mathieu ^a   Znoyko, Sergei ^a   Visconti, Richard P ^a   Zhang, Jing ^a   Hatfield, Corey M ^a   Silver, Richard M ^a   Hoffman, Stanley ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAVEOLIN 1; CAVEOLIN SCAFFOLDING DOMAIN PEPTIDE; CD14 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; COLLAGEN TYPE 1; STROMAL CELL DERIVED FACTOR 1; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL MIGRATION; CHEMOTAXIS; CLINICAL ARTICLE; CONNECTIVE TISSUE CELL; CONTROLLED STUDY; FEMALE; FIBROCYTE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERSTITIAL LUNG DISEASE; LUNG FIBROSIS; MALE; MIGRATION INHIBITION; MONOCYTE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SCLERODERMA; UPREGULATION;

EID: 80051600437     PISSN: None     EISSN: 17551536     Source Type: Journal    
DOI: 10.1186/1755-1536-4-15     Document Type: Article

References (31)

1. Bucala R. Fibrocytes: discovery of circulating connective tissue cell progenitors. Fibrocytes: New Insights Into Tissue Repair and Systemic Fibrosis 2007, Hackensack, NJ, USA: World Scientific.
2. Metchnikov II. Immunity of Infectious Diseases 1901, Paris, France. Masson.
3. Maximow AA. Cultures of blood leucocytes: from lymphocyte and monocyte to connective tissue. Arch Exp Zellforsch 1928, 5:169-268.
4. Cohnheim J. About inflammation and suppuration. Path Anat Physiol Klin Med 1867, 40:1-79.
5. Fischer AC. Transformation outside of organism of mononuclears into fibroblasts. Compt Rend Soc Biol 1925, 92:109-112.
6. Bucala R, Spiegel LA, Chesney J, Hogan M, Cerami A. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol Med 1994, 1:71-81. 2229929, 8790603.
7. Mathai SK, Gulati M, Peng X, Russell TR, Shaw AC, Rubinowitz AN, Murray LA, Siner JM, Antin-Ozerkis DE, Montgomery RR, Reilkoff RA, Bucala RJ, Herzog EL. Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype. Lab Invest 2010, 90:812-823. 10.1038/labinvest.2010.73, 20404807.
8. Phillips RJ, Burdick MD, Hong K, Lutz MA, Murray LA, Xue YY, Belperio JA, Keane MP, Strieter RM. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest 2004, 114:438-446. 484979, 15286810.
9. Mehrad B, Burdick MD, Zisman DA, Keane MP, Belperio JA, Strieter RM. Circulating peripheral blood fibrocytes in human fibrotic interstitial lung disease. Biochem Biophys Res Commun 2007, 353:104-108. 10.1016/j.bbrc.2006.11.149, 17174272.
10. Abe R, Donnelly SC, Peng T, Bucala R, Metz CN. Peripheral blood fibrocytes: differentiation pathway and migration to wound sites. J Immunol 2001, 166:7556-7562.
11. Hartlapp I, Abe R, Saeed RW, Peng T, Voelter W, Bucala R, Metz CN. Fibrocytes induce an angiogenic phenotype in cultured endothelial cells and promote angiogenesis in vivo. FASEB J 2001, 15:2215-2224. 10.1096/fj.01-0049com, 11641248.
12. Andersson-Sjöland A, de Alba CG, Nihlberg K, Becerril C, Ramírez R, Pardo A, Westergren-Thorsson G, Selman M. Fibrocytes are a potential source of lung fibroblasts in idiopathic pulmonary fibrosis. Int J Biochem Cell Biol 2008, 40:2129-2140. 10.1016/j.biocel.2008.02.012, 18374622.
13. Tourkina E, Richard M, Oates J, Hofbauer A, Bonner M, Gööz P, Visconti R, Zhang J, Znoyko S, Hatfield CM, Silver RM, Hoffman S. Caveolin-1 regulates leucocyte behaviour in fibrotic lung disease. Ann Rheum Dis 2010, 69:1220-1226. 10.1136/ard.2009.117580, 2907085, 20410070.
14. Tourkina E, Richard M, Gööz P, Bonner M, Pannu J, Harley R, Bernatchez PN, Sessa WC, Silver RM, Hoffman S. Antifibrotic properties of caveolin-1 scaffolding domain in vitro and in vivo. Am J Physiol Lung Cell Mol Physiol 2008, 294:L843-L861. 10.1152/ajplung.00295.2007, 18203815.
15. Wang XM, Zhang Y, Kim HP, Zhou Z, Feghali-Bostwick CA, Liu F, Ifedigbo E, Xu X, Oury TD, Kaminski N, Choi AM. Caveolin-1: a critical regulator of lung fibrosis in idiopathic pulmonary fibrosis. J Exp Med 2006, 203:2895-2906. 10.1084/jem.20061536, 1850940,1850940, 17178917.
16. Del Galdo F, Sotgia F, de Almeida CJ, Jasmin JF, Musick M, Lisanti MP, Jiménez SA. Decreased expression of caveolin-1 in patients with systemic sclerosis: crucial role in the pathogenesis of tissue fibrosis. Arthritis Rheum 2008, 58:2854-2865. 10.1002/art.23791, 2770094, 18759267.
17. Moore BB, Kolodsick JE, Thannickal VJ, Cooke K, Moore TA, Hogaboam C, Wilke CA, Toews GB. CCR2-mediated recruitment of fibrocytes to the alveolar space after fibrotic injury. Am J Pathol 2005, 166:675-684. 10.1016/S0002-9440(10)62289-4, 1780139, 15743780.
18. Strieter RM, Keeley EC, Hughes MA, Burdick MD, Mehrad B. The role of circulating mesenchymal progenitor cells (fibrocytes) in the pathogenesis of pulmonary fibrosis. J Leukoc Biol 2009, 86:1111-1118. 10.1189/jlb.0309132, 2774878, 19581373.
19. Mehrad B, Burdick MD, Strieter RM. Fibrocyte CXCR4 regulation as a therapeutic target in pulmonary fibrosis. Int J Biochem Cell Biol 2009, 41:1708-1718. 10.1016/j.biocel.2009.02.020, 2681415, 19433312.
20. Gomperts BN, Strieter RM. Fibrocytes in lung disease. J Leukoc Biol 2007, 82:449-456. 10.1189/jlb.0906587, 17550974.
21. Herzog EL, Bucala R. Fibrocytes in health and disease. Exp Hematol 2010, 38:548-556. 10.1016/j.exphem.2010.03.004, 3136351, 20303382.
22. Wang CH, Huang CD, Lin HC, Lee KY, Lin SM, Liu CY, Huang KH, Ko YS, Chung KF, Kuo HP. Increased circulating fibrocytes in asthma with chronic airflow obstruction. Am J Respir Crit Care Med 2008, 178:583-591. 10.1164/rccm.200710-1557OC, 18583572.
23. Aldonyte R, Jansson L, Piitulainen E, Janciauskiene S. Circulating monocytes from healthy individuals and COPD patients. Respir Res 2003, 4:11. 10.1186/1465-9921-4-11, 239032, 14624669.
24. Moeller A, Gilpin SE, Ask K, Cox G, Cook D, Gauldie J, Margetts PJ, Farkas L, Dobranowski J, Boylan C, O'Byrne PM, Strieter RM, Kolb M. Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009, 179:588-594. 10.1164/rccm.200810-1534OC, 19151190.
25. Keeley EC, Mehrad B, Strieter RM. Fibrocytes: bringing new insights into mechanisms of inflammation and fibrosis. Int J Biochem Cell Biol 2010, 42:535-542. 10.1016/j.biocel.2009.10.014, 2835833, 19850147.
26. Postlethwaite AE, Shigemitsu H, Kanangat S. Cellular origins of fibroblasts: possible implications for organ fibrosis in systemic sclerosis. Curr Opin Rheumatol 2004, 16:733-738. 10.1097/01.bor.0000139310.77347.9c, 15577612.
27. Pilling D, Fan T, Huang D, Kaul B, Gomer RH. Identification of markers that distinguish monocyte-derived fibrocytes from monocytes, macrophages, and fibroblasts. PLoS One 2009, 4:e7475. 10.1371/journal.pone.0007475, 2759556, 19834619.
28. Moore BB, Murray L, Das A, Wilke CA, Herrygers AB, Toews GB. The role of CCL12 in the recruitment of fibrocytes and lung fibrosis. Am J Respir Cell Mol Biol 2006, 35:175-181. 10.1165/rcmb.2005-0239OC, 2643255, 16543609.
29. American Rheumatism Association Diagnostic and Therapeutic Criteria Committee Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for Scleroderma Criteria. Arthritis Rheum 1980, 23:581-590. 10.1002/art.1780230510, 7378088, American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.
30. Chen X, Beutler JA, McCloud TG, Loehfelm A, Yang L, Dong HF, Chertov OY, Salcedo R, Oppenheim JJ, Howard OM. Tannic acid is an inhibitor of CXCL12 (SDF-1α)/CXCR4 with antiangiogenic activity. Clin Cancer Res 2003, 9:3115-3123.
31. Keane MP, Belperio JA, Moore TA, Moore BB, Arenberg DA, Smith RE, Burdick MD, Kunkel SL, Strieter RM. Neutralization of the CXC chemokine, macrophage inflammatory protein-2, attenuates bleomycin-induced pulmonary fibrosis. J Immunol 1999, 162:5511-5518.